Miravirsen

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameMiravirsen
Drug Alias NameMiravirsen sodiumLiver-specific microRNA-122 antagonist - RocheLNA-based miR-122 antagonismiR-122 antagonist - RocheSPC-3549 +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionHepatitis C virus replication inhibitorsMIRN122 microRNA inhibitors
TargetsMIRN122 microRNA
Therapy Area/IndicationsHepatitis C, ChronicHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSlovakiaPoland +[7] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSantaris Pharma A/S
Active IndicationsN/A
Inactive IndicationsHepatitis C, ChronicHepatitis C

Other Information

ATC CodeN/A
Related LinksWikipedia